drugset / Trial / NCT05558007

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

NCT05558007

Phase 2 Recruiting 72 enrolled Biozeus Biopharmaceutical S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.

Timeline

Start
2023-11-22
Primary completion
2024-12-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BZ371A Unknown 5 mg/ml Topical
Comparator Tadalafil Small molecule 5 mg Oral